Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07201818 · ClinicalTrials.gov registry record · NA
LET for Fibromyalgia
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT07201818 is a NA study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT07201818, a NA study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
The study is a double blinded, randomized, sham-controlled, parallel group trial conducted at UT Southwestern (UTSW) Medical Center. The purpose of this research study is to determine the effectiveness of Lymphatic Enhancement Technology (LET) treatment in patients with fibromyalgia. Participants will complete assessments of heart rate and blood pressure, pain thresholds to mechanical stimuli, and completion of quality-of-life surveys. In addition, participants will receive four treatments, one time per week, with either an active or sham LET device. Each visit will take between 45 minutes to 2 hours. A follow-up phone call or email from the study team will occur at 4 weeks after completion of the LET treatment. Total study duration is two months.
Interventions
- DEVICE Lymphatic Enhancement Technology (LET)
- DEVICE Sham Lymphatic Enhancement Technology (LET)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-06 |
| Est. Completion | 2028-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07201818
The ClinicalTrials.gov registry entry for NCT07201818 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lymphatic Enhancement Technology (LET) is the first listed.
NCT07201818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07201818 about?
NCT07201818 is a clinical study titled "LET for Fibromyalgia". The study is a double blinded, randomized, sham-controlled, parallel group trial conducted at UT Southwestern (UTSW) Medical Center. The purpose of this research study is to determine the effectiveness of Lymphatic Enhancement Technology (LET) treatment in patients with fibromyalgia. Participants wi...
What is the current status of trial NCT07201818?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-06. Estimated completion is 2028-01.
What interventions are being tested in trial NCT07201818?
The interventions under investigation include: Lymphatic Enhancement Technology (LET) (DEVICE), Sham Lymphatic Enhancement Technology (LET) (DEVICE).
Who is sponsoring clinical trial NCT07201818?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.